Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system.

From 2021 to 2023, there is an increasing trend in the volume of AE reports, with 75 AE reports reported in the first quarter of 2024, as detailed in (Table 1 ).

also in 63,971 other papers